

Neola Medical's Q4 report presentation hosted by Investor Studios

Catch up on the highlights from Neola Medical's year-end Q4 report for 2025. CEO Hanna Sjöström reflects on a year marked by key milestones as we entered the clinical phase, strengthened the organization, and continued to build on our most strategically important assets. CFO David Folkesson presents the financial results for Q4 2025.

Watch the report presentation and stay for the Q&A session here: https://youtube.com/live/-_0FXFp8uXM

For further information, contact:

Hanna Sjöström, CEO

e-mail: hanna.sjostrom@neolamedical.com

David Folkesson, CFO

e-mail: david.folkesson@neolamedical.com

About Neola Medical

Neola Medical AB (publ) develops an innovative medical technology device for non-invasive, continuous lung monitoring and real-time alerts of potentially life-threatening lung complications in preterm born babies. By enabling instant detection, the technology aims to support earlier intervention, improve clinical decision-making, enhance long-term outcomes, and ultimately contribute to saving lives. The patented, cutting-edge technology was developed at Lund University in Sweden and is based on a spectroscopic method that measures changes in lung volume and oxygen gas concentration. Neola Medical builds on Sweden's longstanding legacy of medical technology innovation and contributions to global health care. Neola Medical was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company's Certified Adviser is FNCA Sweden AB.

Image Attachments

[Photo Neola Medical Q4 2025 Report Presentation Hosted By Investor Studios](#)

Attachments

[Neola Medical's Q4 report presentation hosted by Investor Studios](#)